accepted abstracts

Chairs:
Pietro Lampertico and Heiner Wedemeyer

OCTOBER
11-12, 2024
MILAN, ITALY
Fondazione Cariplo - Conference Center

DeltaCure

3rd International **Meeting**

with the support of

UNIVERSITÀ DEGLI STUDI DI MILANO

EpaCS ETS

The StephanUrban Foundation

DIAGNOSIS, STAGING, HCC RISK AND ANTIVIRAL THERAPY

P1 Nearly One-Third of Veterans with Hepatitis Delta Virus Infection in the United States Have Already Developed Cirrhosis or Hepatocellular Carcinoma at Time of Diagnosis

R.J. Wong[1,2], Z. Yang[2], J. Lim[3], J.H. Jou[4,5], R. Cheung[1,2]

[1]Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA; [2]Gastroenterology and Hepatology Section, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA; [3]Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut; [4]Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health & Science University Hospital Portland OR; [5]Division of Gastroenterology and Hepatology, Department of Medicine, Portland VA Medical Center Portland OR

P2 Quantification of plasma HDV RNA in untreated and bulevirtide-treated patients with CHD: a comparison between robogene 2.0, Eurobioplex and altostar

M.P. Anolli[1], S. Uceda Renteria[2], E. Degasperi[1], F. Facchetti[1], D. Sambarino[1], M. Borghi[1], R. Perbellini[1], R. Soffredini[1], S. Monico[1], A. Callegaro[2], P. Lampertico[1,3,4]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [3]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [4]D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P3 Value and kinetics of virological markers in the natural course of chronic hepatitis D virus infection

L. Sandmann[1,2,3], V. Ohlendorf[1], A. Ehrenbauer[1], B. Bremer[1], A.R.M. Kraft[1,3,4,5], M. Cornberg[1,2,3,4,5], K. Deterding[1], H. Wedemeyer[1,2,3,4], B. Maasoumy[1,4]

[1]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany; [2]D-SOLVE consortium, an EU Horizon Europe funded project; [3]Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany; [4]German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; [5]Centre for Individualised Infection Medicine (CiiM), a joint venture between Helmholtz-Centre for Infection Research and Hannover Medical School, Hannover, Germany

P4 Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation

L. Di Marco[1,2], N. De Maria[3], A. Pivetti[3], A. Colecchia[3], A. Romanzi[3], A. Spallanzani[1], G. Guaraldi[4], G. Dolci[4], G. Ciusa[5], F. Di Benedetto[6], P. Magistri[6], S. Di Sandro[6], E. Degasperi[7], M.P. Anolli[7], P. Lampertico[7], D. Giosa[8], D. Lombardo[9], G. Raimondo[9], T. Pollicino[9]

[1]Department of Oncology and Hematology, Oncology Unit, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, Modena, 41124, Italy; [2]Clinical and Experimental Medicine Program, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; [3]Chimomo Department, Gastroenterology Unit, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, 41124 Modena, Italy; [4]Department of Infectious Diseases, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, Modena, 41124, Italy; [5]Infectious Diseases Unit, ARNAS ""Civico-Di Cristina-Benfratelli"", Palermo, Italy; [6]Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, 41124, Italy; [7]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [8]Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy; [9]Department of Internal Medicine, University Hospital of Messina, Messina, Italy

P5 Development and implementation of an hepatitis D detection and linkage to care program in Catalonia. Preliminary results.

A. Palom[1,2], A. Rando-Segura[1,2], L. Calatayud Samper[3], G. Fernandez Rivas[4], A. Sellés Sanchez[5], S. Mormeneo Bayo[6], D. Pérez del Campo[7], M.M.O. Perez Moreno[8], J. Ayats[9], D. Tabernero[1,2], J. Castellote[3], R.M. Morillas[4], J.C. Quer[5], C. Aracil Blanch[6], C. Lopez[7], D. Salazar[8], A. Marco[10], M. Buti[1,2]

[1]Hospital UniversitariValld'Hebron, Barcelona, Spain; [2]Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; [3]Hospital Universitari de Bellvitge, Barcelona, Spain; [4]Hospital Universitari Germans TriasiPujol, Badalona, Spain; [5]Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain; [6]Hospital Universitari Arnau de Vilanova, Lleida, Spain; [7]Hospital Universitari Doctor Josep Trueta, Girona, Spain; [8]Hospital UniversitariVerge de la Cinta de Tortosa, Tarragona, Spain; [9]Microbiology Area of the Clinical Laboratories Directorate, Catalan Institute of Health (ICS), Barcelona, Spain; [10]Penitentiary Health Program, Catalan Institute of Health (ICS), Barcelona, Spain

P6 THE WHO HDV RNA International Standard does not reflect variability of real-world samples

B. Bremer[1], K. Deterding[1], K. Port[1], B. Gey[2], C. Früchtel[2], A. Reinhardt[2], I. Lachmann[2], M. Cornberg[1,3,4,5,6], H. Kefalakes[1,3,4,5], B. Maasoumy[1,5], H. Wedemeyer[1,3,4,5], L. Sandmann[1,3,4]

[1]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover; [2]Roboscreen GmbH, Leipzig; [3]D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917); [4]Excellence Cluster RESIST Hannover Medical School, Hannover; [5]German Center for Infection Research (DZIF), Hannover/Braunschweig; [6]Centre for Individualised Infection Medicine, Helmholtz Centre for Infection Research/Hannover Medical School, Hannover

P7 Bulevirtide: a success case after pegINFα failure

A. Carraro[1], R. Marocco[1], B. Kertusha[1], G. Mancarella[1], L. Ansaldo[1], L. Fondaco[1], S. De Maria[1], S. Corazza[1], A. Gasperin[1], A.Grimaldi[1], C. Del Borgo[1], M. Lichtner[2]

[1]Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome Polo Pontino, Latina, Italy; [2]Department of NESMOS, Sapienza University of Rome, Rome, Italy

P8 The prevalence and characteristics of hepatitis B/D in 48,522 HBsAg tested individuals in Mongolia

G. Jargalsaikhan[1,2] and H. Kamal[3], S.n Enkhtaivan[1,2], D. Bruce[4], B. Dashtseren[1,2], T. Ulziibadrakh[1,2], M. Batkhuu[1,2], P. Bat-Ulzii[1,2], S. Byambabaatar[1,2], N. Dashdorj[1,2] and S. Aleman[3]

[1]The Liver Center, Ulaanbaatar, Mongolia; [2]ONOM Foundation, Ulaanbaatar, Mongolia; [3]The department of Infectious Diseases, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; [4]SDS Life Science statistical consultancy, Stockholm, Sweden

P9 Validation of Streamlined serodiagnosis of hepatitis delta virus

A. Dashdorj[1,2], K. An[3], N. Ariungerel[5], S. Han[3], G. Choi[3], S. Ah Kim[4], T.H. Kim[3], M. Chung[4], O. Oidosambuu[5], B. Ochirsum[2], S. Enkhtaivan[2], Saruul Enkhjargal[5], P. Bat-Ulzii[2], E. Ochirbat[2], N. Dashdorj[1,2], N. Dashdorj[1,2] N.J. Cho[6]

[1]Onom Foundation, Ulaanbaatar; [2]The Liver Center, Ulaanbaatar; [3]Department of Research and Development, Anyang; [4]Department of Chemical Engineering, Hongik University, Seoul; [5]Laboratory of Genetic Engineering, NUM, Ulaanbaatar; [6]School of Materials Science and Engineering, Nanyang Technological University, Singapore

P10 Limited use of established risk scores for the prediction of hepatocellular carcinoma in patients with chronic hepatitis D virus infection

R. Iker[1,2], A. Wranke[1,2], H. Schneider[1], H. Wedemeyer[1,2,3,4], H. Kefalakes[1,2,3,4], L. Sandmann[1,3,4]

[1]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [2]German Center for Infection Research (DZIF), Hannover-Braunschweig Site, Germany; [3]D-SOLVE: EU-funded Network on individualized management of hepatitis D, Hannover, Germany; [4]RESIST Cluster of Excellence, Hannover Medical School, Hannover, Germany

P11 Is there a Hepatitis Delta Virus variant in West Africa, not detected by current serological diagnostic tests?

P. Hamouda[1], A. Gerber[1,2], A. Ramirez Mena[3], V. Delagarde[1,2], B. Wembulua Shinga[3], M. Seydi[3], N. Fatou Ngom[3], O. Ndiaye[3], E. Gordien[1,2], S. Brichler[1,2], G. Wandeler[3], F. Le Gal[1,2]

[1]Centre national de référence des Hépatites virales B, C et Delta, Laboratoire de Microbiologie clinique, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris Cité, Bobigny, France; [2]INSERM, U955 équipe 18, Créteil, France; [3]Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Fann, Dakar, Sénégal

P12 Novel anti-HDV therapies require reliable quantification of plasma HDV RNA: A European multicenter study

A. Reinhardt[9], E. Stelzl[2], J. Kress[3], A. Olivero[4], P. Lampertico[5], A. Heim[6], S. Aberle[7], H. Wedemeyer[8], A. Berger[1], B. Gey[9], C. Früchtel[9], H.H. Kessler[2]

[1]Institute of Medical Virology, Goethe University Frankfurt, Germany; [2]Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Austria; [3]Section of Molecular Virology, Paul-Ehrlich-Institute, Langen, Germany; [4]Gastroenterology and Hepatology Department, "San Giovanni Battista" Hospital and Department of Internal Medicine, University of Torino, Italy; [5]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [6]Hannover Medical School, Institute of Virology, Hannover, Germany; [7]Center for Virology, Medical University of Vienna, Vienna, Austria; [8]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [9]Roboscreen GmbH, Leipzig, Germany

P13 The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects important clinic-pathologic differences

F. Damone[1], P. Colombatto[1], A. Pinna[1], G. Ricco[1], D. Cavallone[1], G. Petralli[1], L. De Stefano[2], B. Coco[1], L. Surace[1], V. Romagnoli[1], F. Oliveri[1], F. Bonino[3] and M. R. Brunetto[1,2]

[1]Hepatology Unit, University Hospital of Pisa, Pisa,Italy; [2] Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy; [3]Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy

P14 Diagnostic performances of different HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study

L. Piermatteo[1], R. Salpini[1], G.P. Caviglia[2], A. Bertoli[3,4], M.R. Brunetto[5,6], B. Bruzzone[7], A. Callegaro[8], C. Caudai[9], D. Cavallone[5,6], L. Chessa[10], F. Coghe[10], N. Coppola[12], N. Cuomo[13], S. D'Anna[1], M. Di Stefano[14], L. Duca[3], F. Facchetti[15], C. Farina[16], D. Ferraro[17], E. Franchin[18], D. Francisci[19], S. Galli[20], A.R. Garbuglia[21], W. Gennari[22], V. Ghisetti[23], P. Lampertico[15,24], N. Marascio[25], S. Menzo[26], V. Micheli[27], G. Niro[28], A. Olivero2, P. Paba[4], C.I. Palermo[29], O. Palmieri[28], S. Paolucci[30], M. Pisaturo[12], T. Pollicino[31], G. Raffa[31], G. Torre[1], O. Turriziani[32], S. Uzzau[33], M. Vatteroni[34], M. Zazzi[35], A. Craxì[17], F. Ceccherini-Silberstein[3], V. Svicher[1] on behalf of the Virology Italian Network Vironet C

[1]Department of Biology, University of Rome "Tor Vergata", Rome, Italy; [2]Department of Medical Sciences, University of Turin, Turin, Italy; [3]Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; [4]Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy; [5]Dept of Clinical and Experimental Medicine, University of Pisa; [6]Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Pisa University Hospital, Italy; [7]Department of Health Sciences, University of Genoa, Genoa, Italy; [8]Medicina di Laboratorio, ASST Bergamo Est, Bergamo, Italy; [9]Microbiology and Virology Unit, Siena University Hospital, Siena, Italy; [10]Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; [11]Laboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, Cagliari, Italy; [12]Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Caserta, Italy; [13]Microbiology and Virology Unit, Domenico Cotugno Hospital, Naples, Italy; [14]Clinical and Surgical Sciences, Section of Infectious Diseases, University Hospital "Riuniti" of Foggia, Foggia, Italy; [15]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [16]Microbiology and Virology Unit, ASST "Papa Giovanni XXIII", Bergamo, Italy; [17]Section of Microbiology and Clinical Microbiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy; [18]Department of Molecular Medicine, University of Padova, Padova, Italy; [19]Infectious diseases laboratory, Santa Maria della Misericordia Hospital, Perugia, Italy; [20]Operative Unit of Clinical Microbiology, IRCCS S. Orsola-Malpighi University Hospital, Bologna, Italy; [21]Laboratory of Virology, "Lazzaro Spallanzani" National Institute for Infectious Diseases, IRCCS, Rome, Italy; [22]Molecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Azienda Ospedaliero Universitaria di Modena, Modena, Italy; [23]Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy; [24]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [25]Unit of Clinical Microbiology, Department of Health Sciences, "Magna Græcia" University, Catanzaro, Italy; [26]Department of Biomedical Sciences and Public Health, Università Politecnica Delle Marche, Ancona, Italy; [27]Laboratory of Clinical Microbiology, Virology and Bioemergencies, Ospedale Sacco, Milan, Italy; [28]Division of Gastroenterology and Endoscopy, Fondazione IRCCS "Casa Sollievo della Sofferenza". 71013 San Giovanni Rotondo, Italy; [29]Policlinico Universitario "Gaspare Rodolico", Catania, Italy; [30]Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; [31]Department of Clinical and Experimental Medicine, University Hospital "G. Martino" Messina, Messina, Italy; [32]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; [33]Department of Biomedical Sciences, University of Sassari, Sassari, Italy; [34]Virology Unit, Pisa University Hospital, Pisa, Italy; [35]Department of Medical Biotechnology, University of Siena, Siena, Italy

P15 **Hepatitis Delta Virus RNA quantification: a story about fruitful collaboration between private company and academic laboratory**

A. Gerber[1], M. Breuer[2], V. Delagarde[1], K. Rottengatter[2], S. Dziri[1], E. Vincent[2], E. Gordien[1], F. Le Gal[1], S. Brichler[1]
[1]Avicenne Hospital, Virology Unit, French National Reference Centre for HDV, Bobigny, France; [2]altona Diagnostics, Hamburg, Germany

P16 **Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5**

J.C. Eichholz [1], B. Bremer[1], H. Wedemeyer[1,2,3,4], B. Maasoumy[1,2], L. Sandmann[1,3,4]
[1]Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; [2]German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; [3]D-SOLVE consortium, an EU Horizon Europe-funded project (no. 101057917); [4]Excellence Cluster RESIST, Hannover Medical School, Hannover, Germany

P17 **Hepatitis Delta infection in individuals living with HIV – multicentric portuguese study**

C. Valente[1], R. Carvalho[1], R. Lino[2], D. Alves[1], R. Aleixo[1], C. Antunes[3], M. Ferreira[3], C. Pineiro[2], P. Vasques[4], I. Casella[4], C. Azevedo[5], R. Serrão[2], A.C. Miranda[3], K. Mansinho[3], T. Teixeira[5]
[1]Infectious Diseases, ULS Coimbra, Coimbra, Portugal; [2]Infectious Diseases, ULS São João, Porto, Portugal; [3]Infectious Diseases, H Egas Moniz, ULS Lisboa Ocidental, Lisboa, Portugal; [4]Infectious Diseases, ULS Arrábida, Setúbal, Portugal; [5]Infectious Diseases, ULS Gaia Espinho, Gaia, Portugal

P18 **HDV RNA assay sensitivity is critical for determining a correct outcome during Bulevirtide antiviral therapy**

I. Carey[1], M. Anderson[2], Z. Cargill[1], S. Shah[1], J. Lok[1], G. Cloherty[2], G. Dusheiko[1], K. Agarwal[1]
[1]Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom; [2]Department on Infectious Diseases, Abbott Diagnostics, Abbott Park, Chicago, IL 60064, United States of America

P19 **Treatment with pegIFNα inhibits cell division-mediated spread of HDV in a humanized mouse model supporting cell proliferation**

A. Volmari[1,2], T. Volz[1,2], L. Allweiss[1,2], M. Luetgehetmann[2,3], S.P. Fletcher[4], M.M. Holdorf[4], R.C. Muench[4], M. Dandri[1,2]
[1]Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [2]German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems site, Germany; [3]Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [4]Gilead Sciences, Foster City, California, United States of America

P20 **Chronic delta hepatitis without efficient treatment poses a greater risk for hepatocellular cancer development than chronic hepatitis B with efficient treatment**

O. Keskin[1], C. Kalkan[2], M. Gumussoy[2], E. Yurdcu[2], Z. Melekoglu Ellik[2], Y. Yilmaz[2], H. Sahin[1], B. Ozturk[1], Y. Emre Parlar[1], R. Idilman[2], M. Bozdayi[2], C. Yurdaydin[2,3]
[1]Hacettepe University School of Medicine; [2]Ankara University School of Medicine; [3]Koc Universtiy School of Medicine

P21 **Complexities of Hepatitis Delta Virus Testing in a High HBV Prevalence Setting in London**

N. Kokkinos[1], T. Kandaswamy Murugesan[1], A. Millar[1], G. Kerry[1], K.N. Wai-Mon[1], E. Nastouli[2], A.M. Geretti[1,3]
[1]North Middlesex University Hospital, London; [2]University College Hospital, London; [3]University of Rome Tor Vergata, Rome

P22 **High frequency of liver cirrhosis in European patients with hepatitis D: Data from a large multicentre study (D-SOLVE and HDV-1000 consortia)**

A. Wranke[1,2,3], H. Kamal[3,4,5], Z. Cargill[6], M. Radu[3,7], E. Degasperi[3,8,9], K. Lindahl[3,4,5], P. Dörge[1,3,10], J. Kahlhöfer[1,3,10,11], K. Agarwal[6], P. Lampertico[3,8,9], F.A. Caruntu[3,7], H. Wedemeyer[1,2,3,12], S. Aleman[3,4,5], I. Carey[6], L. Sandmann[1,3,12]
[1]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [2]German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany; [3]D-SOLVE: EU-funded Network on individualized management of hepatitis D, German; [4]Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; [5]Department of Medicine Huddinge, Infectious Diseases, Karolinska Institute, Stockholm, Sweden; [6]Institute of Liver Studies, King's College Hospital, London, United Kingdom; [7]Institutul de Boli Infectioase, Bucharest, Romania; [8]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [9]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [10]German Center for Infection Research (DZIF), HepNet Study-House/German Liver Foundation, Hannover, Germany; [11]Centre for Individualized Infection Medicine (CiiM), Helmholtz Centre for Infection Research/Hannover Medical School, Hannover, Germany;, [12]Excellence Cluster RESIST, Excellence Initiative Hannover Medical School, Hannover, Germany

CURRENT AND NEW ANTIVIRAL TREATMENTS

P23 Bulevirtide for patients with chronic hepatitis d (CHD) in Italy: a multicenter prospective nationwide real-life study (D-SHIELD)

M.P. Anolli[1], E. Degasperi[1], G. D'Offizi[2], A. Rianda[2], A. Loglio[3], M. Viganò[3], A. Ciancio[4], Y. Troshina[4], M.R. Brunetto[5], B. Coco[5], S. Zaltron[6], M. Milella[7], P. Toniutto[8], L. Marinaro[9], A. Gori[10], A. Federico[11], T.A. Santantonio[12], G. Verucchi[13], F. Morisco[14], A. Mangia[15], S. De Nicola[16], M. Maracci[17], A. Romano[18], P. Gatti[19], R. Zampino[20], M. Persico[21], P. Pozzoni[22], A. Pellicelli[23], N. Coppola[24], F. Pileri[25], M. Tonnini[26], M. Puoti[27], P. Lampertico[1,28]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; [3]Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; [4]Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy; [5]Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; [6]Infectious Disease Department, Spedali Civili Brescia, Brescia, Italy; [7]Infectious Diseases Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; [8]Hepatology and Liver Transplantation Unit, Academic Hospital, University of Udine, 33100 Udine, Italy; [9]SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy; [10]Infectious Disease Unit II, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milano, Italy; [11]Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; [12]Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; [13]Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; [14]Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples ""Federico II"", Naples, Italy; [15]Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; [16]Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy; [17]Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; [18]Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, University of Padova, Padova, Italy; [19]Internal Medicine Unit, Brindisi General Hospital, Brindisi, Italy; [20]Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; [21]Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy; [22]General Medicine Unit, Presidio Ospedaliero, Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy; [23]Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; [24]Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; [25]Division of Internal Medicine and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; [26]Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; [27]School of Medicine and Surgery University of Milano Bicocca; [28]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P24 Virological and clinical outcomes of patients with HDV-related cirrhosis treated with bulevirtide monotherapy for up to 96 weeks: a multicenter european study (SAVE-D)

E. Degasperi[1], M.P. Anolli[1], M. Jachs[2], T. Reiberger[2], V. De Ledinghen[3], S. Metivier[4], G. D'Offizi[5], F. di Maria[5], C. Schramm[6], H. Schmidt[6], C. Zöllner[7], F. Tacke[7], C. Dietz-Fricke[8], H. Wedemeyer[8], M. Papatheodoridi[9], G. Papatheodoridis[9], I. Carey[10], K. Agarwal[10], F. Van Bömmel[1], M.R. Brunetto[12], M. Cardoso[13], G. Verucchi[14], A. Ciancio[15], F. Zoulim[16], S. Aleman[17], N. Semmo[18], A. Mangia[19], M.N. Hilleret[20], U. Merle[21], T.A. Santantonio[22], N. Coppola[23], A. Pellicelli[24], B. Roche[25], X. Causse[26], L. D'Alteroche[27], J. Dumortier[28], N. Ganne[29], F. Heluwaert[30], I. Ollivier[31], D. Roulot[32], M. Viganò[33], A. Loglio[34], A. Federico[35], F. Pileri[36], M. Maracci[37], M. Tonnini[38], J.P. Arpurt[39], K. Barange[40], E. Billaud[41], S. Pol[42], A. Gervais[43], A. Minello[44], I. Rosa[45], M. Puoti[46], P. Lampertico[1,47,48]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; [3]Hepatology Department, Haut-Lévêque Hospital, Bordeaux, France; [4]Hepatology Unit, CHU Rangueil, 31059, Toulouse, France; [5]Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; [6]Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany; [7]Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany; [8]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [9]Department of Gastroenterology, General Hospital of Athens ""Laiko"", Medical School of National & Kapodistrian University of Athens, Greece; [10]Institute of Liver Studies, King's College Hospital, London, UK; [11]Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Laboratory for Clinical and Experimental Hepatology, Leipzig, Germany; [12]Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; [13]Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; [14]Department of Medical and Surgical Sciences, Unit of Infectious Diseases, ""Alma Mater Studiorum"" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; [15]Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy; [16]Lyon Hepatology Institute, Université Claude Bernard Lyon 1; Hospices Civils de Lyon; INSERM Unit 1052 - CRCL; Lyon, France; [17]Department of Infectious Diseases, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden; [18]Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; [19]Liver Unit, Fondazione IRCCS ""Casa Sollievo della Sofferenza"", San Giovanni Rotondo, Italy; [20]Service d'hépato-gastro-entérologie, CHU Grenoble-Alpes, Grenoble, France; [21]Department of Internal Medicine IV, Gastroenterology & Hepatology, Medical University of Heidelberg, Heidelberg, Germany; [22]Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; [23]Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; [24]Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; [25]Hepato-Biliary Center, AP-HP Hôpital Universitaire Paul Brousse, Paris-Saclay University, Research INSERM-Paris Saclay Unit 1193, Villejuif, France; [26]Hôpital de la Source Orleans, France; [27]Service d'Hépato-Gastroentérologie CHU de Tours, France; [28]Department of Digestive Diseases, Hospices Civils de Lyon, Edouard Herriot hospital, France; Claude Bernard Lyon 1 University, France; [29]AP-HP, Avicenne Hospital, Hepatology Department, F-93000 Bobigny, France; [30]Centre Hospitalier Annecy Genevois, 74000 Annecy, France; [31]Department of Hepatogastroenterology, CHU de Caen Normandie, Caen, France; [32]AP-HP, Avicenne hospital, Liver Unit, Sorbonne Paris Nord University, Bobigny, France; [33]Division of Hepatology, Ospedale San Giuseppe, Italy; [34]Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; [35]Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania ""Luigi Vanvitelli"", Naples, Italy; [36]Division of Internal Medicine

and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; [37]Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; [38]Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; [39]Department of Gastroenterology, CH d'Avignon, Avignon, France; [40]Department of Gastroenterology, Toulouse University Hospital, Toulouse, France; [41]Université de Nantes, INSERM UIC 1413, Department of Infectious Diseases, CHU Hôtel Dieu, Nantes, France; [42]Université Paris Cité; Assistance Publique des Hôpitaux de Paris, Hôpital Cochin, Hepatology/Addictology department, Paris, France; [43]Assistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France; [44]CHU Dijon, Service d'Hépato-gastroentérologie et oncologie digestive, Inserm EPICAD LNC-UMR1231, Université de Bourgogne-Franche Comté, Dijon, France; [45]Service d'hépatogastroentérologie, Centre Hospitalier Intercommunal, Créteil; [46]School of Medicine and Surgery University of Milano Bicocca; [47]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [48]D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P25 Bulevirtide monotherapy prevents liver decompensation in patients with hdv-related cirrhosis: a case control study with propensity score weighted analysis

E. Degasperi[1], A. De Silvestri[2], M.P. Anolli[1], D. Sambarino[1], M. Borghi[1], R. Perbellini[1], F. Facchetti[1], R. Soffredini[1], S. Monico[1], V. De Ledinghen[3], S. Metivier[4], M. Jachs[5], T. Reiberger[5], G. D'Offizi[6], C. Dietz-Fricke[7], G. Papatheodoridis[8], M.R. Brunetto[9], G. Verucchi[10], A. Ciancio[11], F. Zoulim[12], A. Mangia[13], M.N. Hilleret[14], T.A. Santantonio[15], N. Coppola[16], A. Pellicelli[17], B. Roche[18], X. Causse[19], L. D'Alteroche[20], J. Dumortier[21], N. Ganne[22], F. Heluwaer[123], I. Ollivier[24], A. Loglio[25], A. Federico[26], F. Pileri[27], M. Maracci[28], M. Tonnini[29], J.P. Arpurt[30], K. Barange[31], E. Billaud[32], S. Pol[33], A. Gervais[34], A. Minello[35], I. Rosa[36], M. Puoti[37], P. Lampertico[1,38,39]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 2Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; [3]Hepatology Department, Haut-Lévêque Hospital, Bordeaux, France; [4]Hepatology Unit, CHU Rangueil, 31059, Toulouse, France; [5]Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; [6]Division of Infectious Diseases - Hepatology, Department of Transplantation and General Surgery, Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, Rome Italy; [7]Department of Gastroenterology, Hepatology Infectious Diseases and Endocrinology at Hannover Medical School, Hannover, Germany; [8]Department of Gastroenterology, General Hospital of Athens ""Laiko"", Medical School of National & Kapodistrian University of Athens, Greece; [9]Department of Clinical and Experimental Medicine, University of Pisa and Hepatology Unit, University Hospital of Pisa, Pisa, Italy; [10]Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; [11]Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy; [12]Hepatology Department, Université Claude Bernard Lyon 1; Hospices Civils de Lyon; INSERM Unit 1052 - CRCL; Lyon, France; [13]Liver Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; [14]Service d'hépato-gastro-entérologie, CHU Grenoble-Alpes, Grenoble, France; [15]Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy; [16]Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, Italy; [17]Liver Unit, San Camillo Hospital, Department of Transplantation and General Surgery, Rome, Italy; [18]Hepato-Biliary Center, AP-HP Hôpital Universitaire Paul Brousse, Paris-Saclay University, Research INSERM-Paris Saclay Unit 1193, Villejuif, France; [19]Hôpital de la Source Orleans, France; [20]Service d'Hépato-Gastroentérologie CHU de Tours, France; [21]Department of Digestive Diseases, Hospices Civils de Lyon, Edouard Herriot hospital, France; Claude Bernard Lyon 1 University, France; [22]AP-HP, Avicenne Hospital, Hepatology Department, F-93000 Bobigny, France; [23]Centre Hospitalier Annecy Genevois, 74000 Annecy, France; [24]Department of Hepatogastroenterology, CHU de Caen Normandie, Caen, France; [25]Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy; [26]Division of Hepatogastroenterology, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; [27]Division of Internal Medicine and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy; [28]Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy; [29]Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; [30]Department of Gastroenterology, CH d'Avignon, Avignon, France; [31]Department of Gastroenterology, Toulouse University Hospital, Toulouse, France; [32]Université de Nantes, INSERM UIC 1413, Department of Infectious Diseases, CHU Hôtel Dieu, Nantes, France; [33]Université Paris Cité; Assistance Publique des Hôpitaux de Paris, Hôpital Cochin, Hepatology/Addictology department, Paris, France; [34]Assistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France; [35]CHU Dijon, Service d'Hépato-gastroentérologie et oncologie digestive, Inserm EPICAD LNC-UMR1231, Université de Bourgogne-Franche Comté, Dijon, France; [36]Service d'hépatogastroentérologie, Centre Hospitalier Intercommunal, Créteil; [37]School of Medicine and Surgery University of Milano Bicocca; [38]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [39]D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P26 Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses

P. Lampertico[1,2], H. Wedemeyer[3], M.R. Brunetto[4,5], P. Bogomolov[6], T. Stepanova[7], M. Bourlière[8], H. Fontaine[9], G. M. Chee[9], D. Manuilov[9], Q. An[9], A. H. Lau[9], B. L. Da[9], J. F. Flaherty[9], R. C. Mercier[9], C. Frenette[9], A. Osinusi[9], G. Sebastian Gherlan[10], A. Streinu-Cercel[11], S. Zeuzem[12], M. Cornberg[3], D. Roulot[13], F. Zoulim[14], S. Aleman[15], and T. Asselah[16]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [2]CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [3]Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [4]Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa; [5]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [6]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [7]Clinic of Modern Medicine, Moscow, Russian Federation; [8]Hôpital Saint Joseph, Marseille, France; [9]Gilead Sciences, Inc., Foster City, CA, USA; [10]Dr. Victor Babes Foundation, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania; [11] National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania; [12]University Hospital Frankfurt, Frankfurt am Main, Germany; [13]Université Sorbonne Paris Nord, Bobigny, France; [14]Hospital Croix Rousee, Lyon, France; [15]Department of Infectious Diseases, Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden; [16]Hôpital Beaujon, Université de Paris, Clichy, France

P27 Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301

P. Lampertico[1,2], S. Aleman[3], M. Brunetto[4,5], A. Blank[6], P. Andreone[7], P. Bogomolov[8], V. Chulanov[9], N. Mamonova[9], N. Geyvandova[10], M. Viacheslav[11], O. Sagalova[12], T. Stepanova[13], G.M. Chee[14], D. Manuilov[14], M. Li[14], A.H. Lau[14], A. Osinusi[14], J. Schulze zur Wiesch[15], M. Cornberg[16], S. Zeuzem[17], H. Wedemeyer[16]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [2]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [3]Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; [4]University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy; [5]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [6]Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany; [7]University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital, Modena, Italy; [8]M.F. Vladimirsky Moscow Regional and Clinical Institute, Moscow, Russian Federation; [9]FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; [10]Stavropol Regional Hospital, Stavropol, Russian Federation; [11]LLC Medical Company Hepatolog, Samara, Russian Federation; [12]South Ural State Medical University, Chelyabinsk, Russian Federation; [13]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [14]Gilead Sciences, Inc., Foster City, CA, USA; [15]Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany; [16]Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [17]Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany

P28 Forty-Eight-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta: Final Results From the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204

T. Asselah[1], V. Chulanov[2], P. Lampertico[3,4], H. Wedemeyer[5], A. Streinu-Cercel[6], V. Pantea[7], S. Lazar[8], G. Sebastian Gherlan[8], P. Bogomolov[9], T. Stepanova[10], V. Morozov[11], V. Syutkin[12], O. Sagalova[13], D. Manuilov[14], R.C. Mercier[14], L. Ye[14], G.M. Chee[14], B.L. Da[14], A.H. Lau[14], A. Osinusi[14], M. Bourlière[15], V. Ratziu[16], S. Pol[17], M.N. Hilleret[18] and F. Zoulim[19]

[1]Hôpital Beaujon APHP, Université de Paris-Cité, INSERM UMR1149, Clichy, France; [2]Sechenov University, Moscow, Russian Federation; [3]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [4]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [5]Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [6]National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania; [7]Toma Ciorbă Infectious Diseases Clinical Hospital, Chişinău, Moldova; [8]Dr. Victor Babes Foundation, University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania; [9]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [10]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [11]LLC Medical Company Hepatolog, Samara, Russian Federation; [12]NV Sklifosovsky Institute of Emergency Medicine, Moscow, Russian Federation; [13]South Ural State Medical University, Chelyabinsk, Russian Federation; [14]Gilead Sciences, Inc., Foster City, CA, USA; [15]Hôpital Saint Joseph, Marseille, France; [16]CH Pitié-Salpêtrière, Paris, France; [17]Hôpital Cochin, Paris, France; [18]Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; [19]Hospital Croix Rousse, Lyon, France

P29 Treatment of chronic hepatitis D with bulevirtide: 1st year report

R. Rapetti,[1] M.G. Crobu,[2-3] R. Minisini,[1] C. Smirne,[1] P. Ravanini,[2] M. Pirisi.[1]

[1]Internal Medicine, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy. Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, Novara, Italy; [2]Laboratory of Molecular Virology, Maggiore della Carità Hospital, 28100 Novara; [3]Clinical Biochemistry Laboratory, Department of Laboratory Medicine, City of Health and Science University Hospital, 10126 Turin, Italy

P30 Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting

O. Wasserman[1], L. Shekhtman[1,2], S.J. Cotler[1], E. Degasperi[3], M.P. Anolli[3], S. Colonia Uceda Renteria[3], D. Sambarino[3], M. Borghi[3], R. Perbellini[3], F. Facchetti[3], F. Ceriotti[4], H. Dahari[1], P. Lampertico[3,5]

[1]Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA; [2]Department of Information Science, Bar-Ilan University, Ramat Gan, Israel; [3]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; [4]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy;[5] CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P31 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the Phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants

T. Asselah[1], A. Streinu-Cercel[2], A. Jucov[3], E. Gane[4], H. Wedemeyer[5], P. Lampertico[6, 7], M.A. Chattergoon[8], P. Wu[8], S. Maciejewski[8], C. Pilowa[8], A. Hassani[8], T. Correll[8], C. Hwang[8], K. Agarwal[9]

[1]Université de Paris Cité, Hôpital Beaujon, AP-HP, INSERM UMR1149, Paris, France; [2]National Institute for Infectious Diseases Matei Bals, Carol Davila University of Pharmacy and Medicine, Bucharest, Romania; [3]Arensia Exploratory Medicine GmbH, Düsseldorf, Germany and Nicolae Testemitanu State University of Medicine and Pharmacy, Chişinău, Moldova; [4]Auckland Clinical Studies, Auckland, New Zealand; [5]Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany; [6]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [7]CRC ""A. M. and A. Migliavacca"" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [8]Vir Biotechnology, Inc., San Francisco, CA; [9]King's College Hospital, London, UK

P32 Improvement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Monotherapy

P. Lampertico[1,2], S. Aleman[3], P. Bogomolov[4], T. Stepanova[5], M. Cornberg[6], S. Ciesek[7], A. Berger[7], D. Manuilov[8], M. Li[8], A.H. Lau[8], B.L. Da[8], G.M. Chee[8], M.R. Brunetto[9,10], S. Zeuzem[11], H. Wedemeyer[6]

[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy; [3]Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; [4]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [5]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [6]Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; [7]Institute for Medical Virology, German Centre for Infection Research, External Partner Site Frankfurt, University Hospital, Goethe University Frankfurt am Main, Frankfurt am Main, Germany; [8]Gilead Sciences, Inc., Foster City, CA, USA; [9]Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [10]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [11]Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany

P33 Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study

K. Agarwal[1], M. Dobryanska[2], A. Jucov[3], P. Kennedy[4], E.J. Gane[5], M.F. Yuen[6], G. Lai-Hung Wong[7], S. Strasser[8], J. Holmes[9], S. Roberts[10], H. Javanbakht[11], J. Stanton[11], N. Shulman[11]

[1]Kings College Hospital, London, United Kingdom; [2]ARENSIA Exploratory Medicine, Kyiv, Ukraine; [3]ARENSIA Exlporatory Medicine, Chisinau; [4]Queen Mary University Hospital, London, United Kingdom; [5]New Zealand Clinical Research, University of Auckland, Auckland, New Zealand; [6]Queen Mary University Hospital, Hong Kong, Hong Kong; [7]Prince of Wales Hospital, Hong Kong, Hong Kong; [8]Royal Prince Alfred Hospital, Sydney, Australia; [9]St. Vincent's Hospital, Melbourne, Australia; [10]The Alfred Hospital, Melbourne; [11]Bluejay Therapeutics, Inc., San Mateo, United States

P34 Treatment of chronic hepatitis delta with bulevirtide in Portugal: data from a real-life cohort

M.F. Cardoso[1], F. Calinas[2], C. Fonseca[3], C. Gouveia[4], A.A. Horta[5], A. M. Vieira[6], M. Machado[7], C. Palmela[4], J. Branco[1], G. Alexandrino[1], A. Martins[1]

[1]Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; [2]Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; [3]Gastroenterology Department, Hospital Garcia de Orta, Almada, Portugal; [4]Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal; [5]Infectious Diseases Department, Centro Hospitalar do Porto, Porto, Portugal; [6]Gastroenterology Department, Centro Hospitalar Universitário do Algarve, Portimão, Portugal; [7]Gastroenterology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal

P35 Detection and characterization of anti-preS1 antibodies in HDV-infected patients under Bulevirtide treatment

Y. Aronthippaitoon[1], N. Szerman[1], E. Roch[1], F. Zoulim[2], C. Sureau[1], C. Gaudy-Graffin[1], and the ANRS HDEP01 Buldelta study group2

[1]INSERM U1259, Morphogenèse et Antigénicité du VIH, des Virus des Hépatites et Émergents, Université de Tours, France; [2]Service d'hépatologie et gastroentérologie, HCL, Hôpital de la Croix Rousse, Lyon; France

P36 Treatment of HDV infection in Solid Organ Transplant with Bulevirtide: a case report

B. Pinchera, A. d'Agostino, E. Trucillo, F. Cuccurullo, A.R. Buonomo, I. Gentile

Federico II Naples, Infectious Disease Department

P37 Patient-Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: A Long-Term Analysis of the Phase 3 MYR301 Trial at 96 Weeks

M. Buti[1,2], H. Wedemeyer[3], S. Aleman[4], V. Chulanov[5], V. Morozov[6], O. Sagalova[7], T. Stepanova[8], R. G. Gish[9,10], A. Lloyd[11], V. Suri[12], D. Manuilov[12], G. M. Chee12, A. O. Osinusi[12], J. F. Flaherty[12], M. Rock[12], C. Kim[12], S. Pandey[13], B. Singh[13], and P. Lampertico[14,15]

[1]Liver Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain; [2]Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD) del Instituto Carlos III, Barcelona, Spain; [3]Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [4]Department of Infectious Diseases, Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden; [5]Department of Infectious Diseases, Sechenov University, Moscow, Russian Federation; [6]LLC Medical Company Hepatolog, Samara, Russian Federation; [7]South Ural State Medical University, Chelyabinsk, Russian Federation; [8]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [9]Robert G. Gish Consultants, LLC, San Diego, CA, USA; [10]Hepatitis B Foundation, Doylestown, PA, USA; [11]Acaster Lloyd Consulting Ltd., London, UK; [12]Gilead Sciences, Inc., Foster City, CA, USA; 13Pharmacoevidence Private Limited, Punjab, India; [14]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [15]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P38 Real life experience of HBV/HDV-related compensated cirrhosis treatment in an Italian prison. A case report.

G. Quartini[1], C. Di Giuli[1], A. Lavagna[1], A. Marozzo[3], D. Francisci[2].

[1]Infectious Disease Clinic, Ospedale Santa Maria Terni, Università degli Studi di Perugia, Terni; [2]Infectious Disease Clinic, Ospedale Santa Maria della Misericordia, Università degli Studi di Perugia, Perugia; [3]Penitentiary medicine, Italian prison in Terni, Umbria

P39 Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy

F. Zoulim[1], V. Chulanov[2], P. Lampertico[3,4], H. Wedemeyer[5], A. Streinu-Cercel[6,7], V. Pantea[8], S. Lazar[9], G.S. Gherlan[7,10], P. Bogomolov[11], T. Stepanova[12], V. Morozov[13], V. Syutkin[14], O. Sagalova[15], D. Manuilov[16], R.C. Mercier[16], L. Ye[16], G.M. Chee[16], B.L. Da[16], A.H. Lau[16], A. Osinusi[16], M. Bourlière[17], V. Ratziu[18], S. Pol[19], M.N. Hilleret[20], T. Asselah[21]

[1]Hospital Croix Rousse, Hospices Civils de Lyon, INSERM, Université Claude Bernard Lyon 1, Lyon, France; [2]Sechenov University, Moscow, Russian Federation; [3]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; [4]CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy; [5]Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany; [6]Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; [7]"Carol

Davila" University of Medicine and Pharmacy, Bucharest, Romania; [8]Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; [9]Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital, Bucharest, Romania; [10]Dr. Victor Babes Foundation, Bucharest, Romania; [11]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [12]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [13]LLC Medical Company "Hepatolog," Samara, Russian Federation; [14]Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; [15]South Ural State Medical University, Chelyabinsk, Russian Federation; [16]Gilead Sciences, Inc., Foster City, CA, USA; [17]Hôpital Saint Joseph, Marseille, France; [18]CH Pitié-Salpêtrière, Paris, France; [19]Hôpital Cochin, Paris, France; [20]Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; [21]Hôpital Beaujon APHP, Université de Paris-Cité, INSERM, Clichy, France

P40 Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta

F. Zoulim[1], T. Asselah[2], V. Chulanov[3], A. Streinu-Cercel[4,5], G.S. Gherlan[5,6], P. Bogomolov[7], T. Stepanova[8], V. Morozov[9], O. Sagalova[10], R.C. Mercier[11], L. Ye[11], D. Manuilov[11], A.H. Lau[11], G.M. Chee[11], B.L. Da[11], M. Bourlière[12], H. Wedemeyer[13], P. Lampertico[14,15]

[1]Hospital Croix Rousse, Lyon, France; [2]Hôpital Beaujon APHP, Université de Paris, INSERM, Clichy, France; [3]Sechenov University, Moscow, Russian Federation; [4]Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; [5]"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; [6]Dr. Victor Babes Foundation, Bucharest, Romania; [7]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [8]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [9]LLC Medical Company "Hepatolog," Samara, Russian Federation; [10]South Ural State Medical University, Chelyabinsk, Russian Federation; [11]Gilead Sciences, Inc., Foster City, CA, USA; [12]Hôpital Saint Joseph, Marseille, France; [13]Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany; [14]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [15]Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy

P41 High Rates of Adherence to Bulevirtide Monotherapy for Chronic Hepatitis Delta Through 96 Weeks: Results From an Interim Analysis of the Phase 3 Study MYR301

S. Aleman[1], H. Wedemeyer[2], M.R. Brunetto[3,4], A. Blank[5], P. Andreone[6], P. Bogomolov[7], V. Chulanov[8], N. Mamonova[8], N. Geyvandova[9], V. Morozov[10], O. Sagalova[11], T. Stepanova[12], B.L. Da[13], D. Manuilov[13], G.M. Chee[13], M. Li[13], A.H. Lau[13], J. Schulze zur Wiesch[14], M. Cornberg[2], S. Zeuzem[15], P. Lampertico[16,17]

[1]Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; [2]Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hannover, Germany; [3]Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; [4]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; [5]Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; [6]Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy; [7]State Budgetary Institution of Health Care of Moscow Region "Moscow Regional Research Clinical Institute Named After M.F. Vladimirsky," Moscow, Russian Federation; [8]FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation; [9]Stavropol Regional Hospital, Stavropol, Russian Federation; [10]LLC Medical Company "Hepatolog," Samara, Russian Federation; [11]South Ural State Medical University, Chelyabinsk, Russian Federation; [12]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [13]Gilead Sciences, Inc., Foster City, CA, USA; [14]Universitätsklinikum Hamburg-Eppendorf Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany; [15]Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany; [16]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [17]Department of Pathophysiology and Transplantation, CRC "A.M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy

P42 Improvements in Fibrosis and Necroinflammation With Bulevirtide Combined With Pegylated Interferon for Chronic Hepatitis Delta

D. Roulot[1], F. Zoulim[2], V. Chulanov[3], V. Pantea[4], S. Lazar[5], G. Placinta[6], G.S. Gherlan[7,8], P. Bogomolov[9], T. Stepanova[10], V. Morozov[11], V. Syutkin[12], O. Sagalova[13], R.C. Mercier[14], D. Manuilov[14], L. Ye[14], D. Tedesco[14], M. Bourliere[15], M.N. Hilleret[16], T. Asselah[17]

[1]AP-HP, Hôpital Avicenne, Unité d'hépatologie, Université Paris 13, Bobigny; Inserm U955, équipe 18, Université Paris-Est, Créteil; [2]Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM Unit 1052, Lyon Hepatology Institute, Lyon, France; [3]Sechenov University, Infectious Diseases Department, Moscow, Russian Federation; [4]Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; [5]Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital, Bucharest, Romania; [6]State University of Medicine and Pharmacy "Nicolae Testemitanu," Infectious Clinical Hospital "T. Ciorba," Chisinau, Moldova; [7] Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; [8]Dr. Victor Babes Foundation, Bucharest, Romania; [9]M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; [10]LLC Clinic of Modern Medicine, Moscow, Russian Federation; [11]LLC Medical Company "Hepatolog," Samara, Russian Federation; [12]Institute of Emergency Medicine n.a. NV Sklifosovsky, Moscow, Russian Federation; [13]South Ural State Medical University, Chelyabinsk, Russian Federation; [14]Gilead Sciences, Foster City, CA, USA; [15]Hôpital Saint Joseph, Marseille, France; [16]Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; [17]Université de Paris-Cite, Department of Hepatology, Hôpital Beaujon AP-HP, Centre de Recherche sur l'Inflammation, INSERM UMR1149, Clichy, France

P43 Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 24 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301

S. Aleman[1], P. Lampertico[2,3], M. Brunetto[4,5], P. Bogomolov[6], V. Chulanov[7], T. Stepanova[8], A. Lichtman[9], R.C. Mercier[9], D. Manuilov[9], S. Arterburn[9], A. Osinusi[9], F. Christian-Cox[9], M. Cornberg[10], S. Zeuzem[11], H. Wedemeyer[12]

[1]Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore, [2]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [3]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [4]University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy, [5]University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, [6]State Budgetary Institution of Health Care of Moscow Region "Moscow Regional Research Clinical Institute Named After M.F. Vladimirsky", Moscow, Russian Federation, [7]Sechenov University, Moscow, Russian Federation, [8]Limited Liability Company "Clinic of Modern Medicine", Moscow, Russian Federation, [9]Gilead Sciences, Inc., Foster City, United States, [10]Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Hannover, Germany, [11]Department of Medicine, University Hospital, Goethe-University, Frankfurt, Germany, [12]Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Hannover, Germany, RESIST, DZIF and D-Solve

VIROLOGY AND PATHOGENESIS

P44 HIV-HBV-HDV co-infection. Case presentation.

M.N. Radu[1], C. Tudoran[1], R.B. Băloi[1], F.A. Căruntu [1,2]
[1]Department Adults 1, National Institute for Infectious Diseases "Prof. Dr. Matei Bals"(INBIMB), Bucharest; [2]Department of Infectious Disease, University of Medicine and Pharmacy "Carol Davila", Bucharest

P45 Differential patterns of HBV rna and HBcrAG levels in a large european cross-sectional study of untreated patients with chronic hepatitis delta

E. Degasperi[1], C. Scholtes[2,3,4,5], B. Testoni[3,4,5], S. Uceda Renteria[6], M.P. Anolli[1], C. Charre[7,8], F. Facchetti[1], M.L. Plissonnier[3,4,5], D. Sambarino1, R. Perbellini1, S. Monico[1], A. Callegaro[6], E. García-Pras[9], S. Lens[9], M.F. Cortese[10], X. Forns[9], S. Pérez-del-Pulgar[9], M. Heil[11], M. Levrero[3,4,5,12,13], F. Zoulim[3,4,5,13], P. Lampertico[1,14,15]
[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]Virology Department, Hospices Civils de Lyon (HCL) and Université Claude Bernard Lyon 1 (UCBL1), Lyon, France; [3]INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France; [4]University of Lyon, Université Claude-Bernard (UCBL), Lyon, France; [5]The Lyon Hepatology Institute (IHU EVEREST), Lyon, France; [6]Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [7]INSERM U1016, CNRS, UMR8104, Paris France; [8]Virology Department, Hôpital Cochin, APHP, Paris France; [9]Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain; [10]Liver unit, Group of Microbiology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, CIBEREHD, Barcelona, Spain; [11]Roche Molecular Diagnostics, Pleasanton, California, USA; [12]Department of Internal Medicine, SCIAC and the IIT Center for Life Nanoscience, Sapienza University, Rome, Italy; [13]Hepatology Department, Hospices Civils de Lyon (HCL); [14]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [15]D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917)

P46 HELZ2 is an interferon stimulated gene with antiviral properties against Hepatitis Delta Virus

C. Authier[1], C. Eber[2], R. Fouillé[1], C. Bach[2], C. Pons[1], E. Charles[2], E. Huntzinger[3], M. Rivoire[4], G. Passot[5], M. Michelet[6], M. Oudot[2], T.F. Baumert[2], A. Salvetti[1], B. Seraphin[3], D. Durantel[1], .E. Verrier[2] and J. Lucifora[1]
[1]CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France; [2]Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR_S1110, Strasbourg, France; [3]IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104, Inserm U 1258, Université de Strasbourg, Illkirch, France; [4]Centre Léon Bérard (CLB), INSERM, U1032, Lyon, France; [5]Service de chirurgie générale et oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon Et CICLY, EA3738, Université Lyon 1; [6]INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard, Lyon, France

P47 Hospitalised Adults With Hepatitis Delta Virus Infection Have Higher Risk of Disease Progression Than Those With Hepatitis B Virus Monoinfection in Italy

P. Lampertico[1,2], V. Perrone[3], L. Degli Esposti[3], M. Leogrande[3], C. Kim[4], and M. Rock[4]
[1]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [2]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [3]CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy; [4]HEOR — Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA

P48 Baseline characteristics and risk of liver-related events in hepatitis B and C coinfection with and without hepatitis D infection

L.E. Telep[1], A.W. Singer[1], K.M. Kwon[1], A.E. Stead[1], A.P. Chokkalingam[1]
Gilead Science, Fost City, CA, USA

P49 TIGIT-expression on natural killer cell subsets correlate with liver inflammation and bulevirtide treatment response in chronic hepatitis D

P.C. Chen[1,4], K. Deterding[1], S.A.Engelskircher[1], M. Cornberg[1,2,3,6], A. Kraft[1,2], N.K Björkström[5], N. Woller[1,2], and H. Wedemeyer[1,2,3]
[1]Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover; [2]German Center for Infection Research (DZIF), partner site Hannover-Braunschweig; [3]Cluster of Excellence RESIST, Hannover Medical School, Hannover; [4]ZIB program, Hannover Medical School, Hannover; [5]Center of Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm; [6]Centre for Individualized Infection Medicine (CIIM), Hannover

P50 Adenine Base editing of Hepatitis B surface antigen potently inhibits HDV

A. Kumar[1,2,3], E. Combe[1,2,3], E.M. Smekalova[4], S. Dejene[4], C-Y. Chen[1], L. Mougené [1,2,3], M.G. Martinez[1], G. Ciaramella[4], M.S. Packer[4], B. Testoni[1,2,3], F. Zoulim[1,2,3,5]
[1]INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France; [2]University of Lyon, Universite Claude-Bernard (UCBL), Lyon, France; [3]The Lyon Hepatology Institute EVEREST, Lyon, France; [4]Beam Therapeutics, Cambridge, MA, USA; [5]Department of Hepatology, Croix Rousse hospital, Hospices Civils de Lyon, Lyon, France

P51 Sequence Analysis of the Hepatitis D Virus (HDV) Across Genotypes shows Highly Conserved Regions and Evidence of Recombination

S. Chowdhury[1,2], C. Jacobsen[1,2], D. Depledge[2,4,5], H. Wedemeyer[1,2,3,4], L. Sandmann[1,2,3] and H. Kefalakes[1,2,3,4]
[1]Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; [2]Cluster of Excellence RESIST, EXC-2155, Hannover Medical School, Hannover, Germany; [3]European D-SOLVE Consortium; [4]German Center for Infection Research, Partner Site Hannover-Braunschweig; [5]Institute of Virology, Hannover Medical School, Hannover, Germany

P52 Deciphering the cellular response to IFN treatment in HDV-infected cells

C. Eber[1], R. Fouillé[2], E. Gerges[1], T.F. Baumert[1,3,4], D. Durantel[2], J. Lucifora[2], E.R. Verrier[1]
[1]University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg; [2]CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France; [3]Institut hospitalo-universitaire (IHU). Service d'hépato-gastroentérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; [4]Institut Universitaire de France (IUF), Paris, France

P53 Epidemiology and natural history of chronic hepatitis B and D infections in France from 2013 to 2022

T. Asselah[1], V. Loustaud-Ratti[2], J.P. Bronowicki[3], E. Maugain[4], A. Le Blevec[4], C. Idelovici-Marchal[4], C. Lacueille[5], E. Lambourg[5], S. Larrieu[5], Charlotte Colombi[4]
[1]Hôpital Beaujon Clichy - France , [2]CHU Limoges – France , [3]CHU Nancy – France , [4]Gilead Sciences, [5]Horiana Bordeaux - France

P54 Healthcare Resource Utilisation and Costs Among Terminal, Hospitalised Adults With Hepatitis Delta Virus or Hepatitis B Virus Monoinfection in Italy

P. Lampertico[1,2], V. Perrone[3], L.D. Esposti[3], M. Leogrande[3], C. Kim[4], M. Rock[4]
[1]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; [2]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; [3]CliCon S.r.l. Societá Benefit, Health, Economics & Outcomes Research, Bologna, Italy; [4]HEOR – Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA

P55 Rational immunotherapy design for clinical development against HDV using a synthetic DNA-prime and protein-boost strategy

G. Ahlén[1], L. Frelin[1], J. Yan[1], C. Bin Ahn Nordström[1], P. Cunnah[2], A. Ricardo[2], N. Mertens[3], R. Bethell[4], and M. Sällberg[1]
[1]Karolinska Institutet, Stockholm; [2]Rodon Biologics, Oeiras; [3]Bionmer, Antwerpen

P56 Development of a rapid test for HDV-specific T cell characterization in whole blood

N. Le Bert[1], F. Facchetti[2], A.T. Tan[1], M.P. Anolli[2], S. Hariharaputran[1], S.K. Hang[1], E. Degasperi[2], A. Bertoletti[1], P. Lampertico[2,3]
[1]Emerging Infectious Diseases, Duke-NUS Medical School, Singapore ;[2]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [3]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Italy

P57 HDV persistence can be independent from the extent of HBV reservoir and can be sustained by HBsAg production mainly derived from HBV-DNA integration

S. D'Anna[1], L. Piermatteo[1], G. Brancaccio[2], E. Teti[3], A. Di Lorenzo[3], I. Grossi[1], G. Torre[1], V. Malagnino[3], M. Iannetta[3], F. Ceccherini-Silberstein[4], C. Pasquazzi[5], U. Cillo[6], A. Vitale[6], E. Gringeri[6], M. Magrofuoco[6], M. Pacenti[7], L. Baiocchi[8], S. Francioso[8], I. Lenci[8], A. Koffas[9], A.M. Geretti[10], M. L. Abate[11], A. Olivero[11], G. B. Gaeta[12], L. Sarmati[3], M. Rizzetto[11], U. Gill[9], P. Kennedy[9], G. P. Caviglia[11], V. Svicher[1], R. Salpini[1]
[1]Department of Biology, Tor Vergata University, Rome, Italy; [2]Department of Molecular Medicine, Infectious Diseases, University of Padua, Padua, Italy; [3]Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy; [4]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; [5]Sant'Andrea Hospital, Rome, Italy; [6]Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; [7]Microbiology and Virology Unit, Padova University Hospital, Padua, Italy; [8]Hepatology Unit, Policlinico Tor Vergata, Rome, Italy; [9]Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; [10]Department of Systems Medicine, Infectious Disease Clinic, University of Rome Tor Vergata, Rome, Italy; [11]Department of Medical Sciences, University of Turin, Turin, Italy; [12]Infectious Disease Unit, University L. Vanvitelli, Naples, Naples, Italy

P58 Low expression of circulating liver-enriched miRNAs in anti-HDAg patients in absence of active viral replication.

M.F. Cortese[1,2], J. Pérez Garreta[1], B. Pacin Ruiz[1], A. Palom[2,4], D. Tabernero[1,2], A. Rando Segura[1,2,4], E. Vargas Accarino[2,3], J.C. Ruiz Cobo[2,3], M. Riveiro Barciela[2,3,5], M. Buti[2,3,5]
[1]Microbiology, Liver unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [2]Instituto de Salud Carlos III, Centro de investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; [3]Department of hepatology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [4]Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [5]Universitat Autònoma de Barcelona, Bellaterra, Spain

P59 Real world patient profile for individuals with hepatitis delta virus infection treated with bulevirtide 2mg in Europe

L.E. Telep[1], C. Kim[1], K.M. Kwon[1]
Gilead Sciences, Foster City, CA, USA

P60 High diversity of the TCR repertoire in hepatitis delta virus patients with undetectable viral RNA

M.F. Cortese[1,2], A. Palom[2,3], B. Pacín Ruiz[1,2], F. Rudilla[4,4], E. Enrich Randé[4,5], M. Antón Iborra[5], J.C. Ruiz-Cobo[2,3], D. Tabernero[1,2,6], M. Riveiro Barciela[3,7], A. Rando-Segura[1, 2,8,9], M.J. Herrero[4,5], M. Butí[2,3,7]
[1]Department of microbiology, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [2]Carlos III Health Institute, Network Center For Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain; [3]Department of Hepatology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, [4]Histocompatibility and Immunogenetics Laboratory, Banc de Sang i Teixits, Barcelona, Spain, [5]Transfusional Medicine Group, Vall d'Hebron Research Insititute- Universitat Autònoma de Barcelona, Barcelona, Spain; [6]Liver Disease, Viral hepatitis laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [7]Universitat autonoma de Barcelona (UAB), Barcelona, Spain; [8]Department of Microbiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

P61 **Dichotomy between HBcrAg and pre-genomic HBV RNA in relation to HDV RNA response in patients with chronic hepatitis delta during bulevirtide treatment**

Z. Cargill[1], M. Andreson[2], J. Lok[1], S. Shah[1], G. Cloherty[2], G. Dusheiko[1], K. Agarwal[1], I. Carey[1]
[1]Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom; [2]Department of Infectious Diseases, Abbott Diagnostics, North Chicago, Illinois, United States of America

P62 **Plasma pre-S1 HBsAg levels during antiviral therapy with Bulevirtide in chronic hepatitis delta patients – any help in predicting response to therapy?**

Z. Cargill[1], M. Anderson[2], J. Lok[1], S. Shah[1], G. Cloherty[2], G. Dusheiko[1], K. Agarwal[1], I. Carey[1]
[1]Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom; [2]Department of Infectious Diseases, Abbott Diagnostics, North Chicago, Illinois, United States of America

P63 **HDV co-infection and HCV eradication in persons with HIV (PWH): data from the ICONA cohort**

A. Tavelli[1], R. Rossotti[2], V. Malagnino[3], V. Svicher[4], E Quiros-Roldan[5], A. Bandera[6], F.M. Fusco[7], M. Rivano Capparuccia[8], G.B. Gaeta[9], A. Antinori[10], M. Puoti[2], A d'Arminio Monforte[1]
[1]ICONA Foundation, Milan, Italy; [2]Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Ca' Granda Hospital, Milan, Italy; [3]Department of Medicine of Systems, University of Rome Tor Vergata, Rome, Italy; [4]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; [5]University of Brescia and ASST Spedali Civili of Brescia, Department of Infectious and Tropical Diseases, Brescia, Italy; [6]Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCCS Ca, Granda, Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milano Milan, Italy; [7]UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, P.O. "D. Cotugno", Naples, Italy; [8]Infectious and Tropical Disease Unit, Policlinico Umberto I, Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy; [9]University L. Vanvitelli, Infectious Diseases Unit, Naples, Italy; 10Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS

P64 **Role of intrahepatic HDV reservoir in potentially modulating response to bulevirtide treatment at 24 weeks.**

A. Di Lorenzo[1,2], S. D'Anna[3], D. Kontogiannis[2], C. Sorace[2], A. Crea[2], E. Teti[2], V. Malagnino[2], L. Piermatteo[3], I. Grossi[3], C. Castelli[3], M. Nezzo[4], B. Carreri[4], A.M. Geretti[1,2], V. Svicher[3], R. Salpini[3], L. Sarmati[1,2]
[1]Tor Vergata University, Via Montpellier, 1 - 00133 Rome, Italy; [2]Department of Systems Medicine, Infectious Disease Clinic, Viale Oxford, 81- 00133 Rome, Italy; [3]Department of Biology, University of Rome Tor Vergata; [4]Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy

P65 **Integrative transcriptomics and epigenomics reveals a viral footprint of chronic HDV infection in HBV co-infected chimeric livers**

Y. Simanjuntak[1], T.F. Baumert[1,2,3,4], J. Lupberger[1] and the D-Solve consortium
[1]University of Strasbourg, Institute of Translational Medicine and Liver Diseases (ITM), Inserm UMR_S1110, Strasbourg, France; [2]Gastroenterology and Hepatology Service, Strasbourg University Hospitals, France; [3]Institut Universitaire de France, Paris, France; [4]IHU Strasbourg, France

P66 **Adaptive immunity may drive treatment outcome of pegylated IFN alpha in patients with chronic hepatitis D**

M. Anim[1,2], L. Sandmann[1,2,3,4], B. Bremer[1], H. Wedemeyer[1,2,3,4] and H. Kefalakes[1,2,3,4] on behalf of the HIDIT-II study group
[1]Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, [2]D-SOLVE Consortium, [3]Cluster of excellence RESIST (EXC-2155), [4]German Center for Infection Research, Partner Site Hannover-Braunschweig (DZIF)

The Poster Sessions have been realized with the support of DZIF